Deutsche Bank AG (DB, DBK.XE) said Wednesday it will book a EUR257 million impairment charge in the first quarter from exiting its exposure to generic drug maker Actavis, which will be sold to U.S. competitor Watson Pharmaceuticals Inc (WPI).

"The transaction is expected to close in the fourth quarter of 2012," and will lead to a Core Tier 1 capital accretion of approximately EUR290 million, Deutsche Bank said.

Actavis in a separate statement said Wednesday that it will be bought by U.S. peer Watson in a EUR4.5 billion ($5.92 billion) deal.

Actavis was taken private in 2007 by Icelandic billionaire Thor Bjorgolfsson's private-equity firm Novator in a roughly $5 billion deal. The chunk of the leverage buyout loan came from German lender Deutsche Bank. Actavis then went on an acquisition spree, snapping up generic-drug companies all over the world, building a big debt load in the process.

Deutsche Bank, which will release its first-quarter figures Thursday, reportedly took charge at Actavis when a big chunk of Mr. Bjorgolfsson's wealth was wiped out in late 2008 through the collapse of Icelandic bank Landsbanki Islands hf, making a restructuring of Actavis debt necessary.

-By Eyk Henning, Dow Jones Newswires; +49 (0)69 29725 108; eyk.henning@dowjones.com

Watson (NYSE:WPI)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Watson Charts.
Watson (NYSE:WPI)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Watson Charts.